AJP - Regu Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 284: R928-R935, 2003; doi:10.1152/ajpregu.00633.2002
0363-6119/03 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hou, X.
Right arrow Articles by Chemtob, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hou, X.
Right arrow Articles by Chemtob, S.
Vol. 284, Issue 4, R928-R935, April 2003

Increased platelet-activating factor-induced periventricular brain microvascular constriction associated with immaturity

Xin Hou1, Fernand Gobeil Jr.1, Anne Marilise Marrache1,2, Christiane Quiniou1, Sonia Brault1,2, Daniella Checchin1,2, Sylvie G. Bernier1, Florian Sennlaub1, Jean-Sebastien Joyal1, Daniel Abran3, Krishna Peri3, Daya R. Varma2, and Sylvain Chemtob1,2

1 Centre de Recherche de l'Hôpital Sainte-Justine, Department of Pediatrics and Pharmacology, Université de Montréal, Montréal, H3T 1C5; 2 Department of Pharmacology and Therapeutics, McGill University, Montréal, H3G 1Y6; and 3 Theratechnologies, Ville St-Laurent, Quebec, Canada, H4S 2A4


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Oxidant stress contributes to the pathogenesis of hypoxic-ischemic encephalopathies. Platelet-activating factor (PAF) is generated during oxidant stress. We studied the vasomotor mode of actions of PAF on periventricular (PV) microvessels of fetal (approx 75% of term), newborn (1-3 days), and adult pigs. PAF constricted PV microvessels from fetal (29.27 ± 2.6%) and newborn (22.14 ± 3.2%) pigs but was ineffective in adults (<2.5%). Specific [3H]PAF binding was greater in fetus and newborn than in adults; a concordant developmental PAF-induced inositol phosphate formation was observed. PAF-induced vasoconstriction was abrogated by thromboxane A2 (TXA2) synthase and receptor inhibitors, calcium channel blockers, and by removal of endothelium; vasoconstriction to TXA2 mimetic U-46619 did not differ with age. Immunoreactive TXA2 synthase expression and PAF-evoked TXA2 formation revealed a fetus> newborn>adult profile. Thus the greater PAF-induced PV microvascular constriction in younger subjects seems attributable to greater PAF receptor density and mostly secondary to TXA2 formation from endothelium. The resulting decrease in blood flow may contribute to the increased vulnerability of the PV brain regions to oxidant stress-induced injury in immature subjects.

peroxidation; age dependence; thromboxane; ischemia


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

OXIDANT STRESS PLAYS a major role in the pathogenesis of various disorders, such as hypoxic-ischemic encephalopathies (38, 42), including periventricular leukomalacia in premature subjects (41, 42). Free radicals can alter brain hemodynamics by causing vasoconstriction (19, 37) and increasing thromboxane A2 (TXA2) formation (1, 26). Although TXA2 has been implicated in peroxidation-induced vasoconstriction (1, 23), the mechanisms of TXA2 production by brain vasculature during oxidant stresses are complex and not fully understood.

Oxidation leads to the activation of a number of pathways and the formation of various factors. An early and important event following peroxidation is the activation of phospholipase A2 (3, 7), which leads to the synthesis of agents with major vascular actions, including platelet-activating factor (PAF) (30, 35). PAF is a phospholipid with diverse biological functions mediated by a G protein-coupled receptor. The production and release of PAF in the brain have been reported under various pathological conditions, including oxidant stress-induced ischemic injury in newborn (4, 25). PAF is a modulator of vasomotor tone and induces pulmonary, coronary, and cerebral vasoconstriction (5, 10, 22). The mechanism of the vascular action of PAF is controversial, but many investigators have shown that some of its effects might be mediated through the formation of cyclooxygenase products of arachidonic acid metabolism in response to activation of PAF receptors (11, 22). However, the direct effects of PAF on brain intraparenchymal vasculature, implicated in the genesis of periventricular ischemic encephalopathies, remain unknown.

Because oxidant stress-induced encephalopathies are mostly localized to the periventricular region in immature subjects compared with older ones (42), we postulated that the constrictor effects of PAF on the microvessels of the periventricular brain region are more pronounced in immature than older subjects, and in this process we evaluated the effects of PAF on these microvessels as well as the role of TXA2 in these vascular responses.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Tissue preparation. Animals were used according to a protocol of the Animal Care Committee of Hôpital Sainte-Justine along with the principles of the Guide for the Care and Use of Experimental Animals of the Canadian Council on Animal Care. Brains from fetal [78-90 days gestation (term 114 days)] and adult (6-8 mo old) pigs were obtained from an abattoir (St-Hélène, Québec, Canada) immediately after exsanguination of sows transported in ice-cold buffer to the laboratory. Newborn pigs (1-3 days old) were acquired from Fermes Ménard (L'Ange-Gardien, Québec, Canada). Animals were anesthetized with halothane (~2.5-5%) and killed with pentobarbital sodium (120 mg/kg). The brains were removed and placed immediately in ice-cold Krebs buffer (pH 7.4) of the following composition (in mM): 120 NaCl, 4.5 KCl, 2.5 CaCl2, 1.0 MgSO4, 27 NaHCO3, 1.0 KH2PO4, and 10 glucose; 1.5 U/ml heparin was added to the buffer. For biochemical measurements, tissues were frozen in liquid N2 and stored at -80°C.

Vasomotor response of brain periventricular microvessels. Slices of brain (1-mm thick) exposing the periventricular brain region were prepared as previously described (12, 20) to study relatively undisturbed penetrating microvessels (30-50 µm) reported to contribute significantly to the control of cerebral vascular resistance (17). The brain slices were pinned securely to a wax base of a 20-ml bath containing Krebs buffer (pH 7.4) equilibrated with 95% O2-5% CO2 and maintained at 37°C. The preparations were washed two to three times with fresh buffer and allowed to equilibrate for 45 min before starting the experiment.

Cerebral microvessels were visualized and recorded using a video camera (model CCD72, MTI) mounted on a dissecting microscope (model M-400, Nikon), as reported previously (12, 20). Vascular diameter was measured using a digital image analyzer (Sigma Scan software, Jandel Scientific, Corte Madera, CA) and repeated three times with a variability of <1%. Vascular diameter was recorded before and after topical application of increasing concentrations of test agents (C-PAF, thromboxane mimetic U-46619, and PGF2alpha ) in the presence and absence of a 20-min pretreatment with the following agents at known effective concentrations (1, 15, 20): TXA2 synthase inhibitor CGS-12970 (1 µM); TXA2 receptor antagonist L-670596 (0.1 µM); PAF receptor antagonist THG-315 (1 µM); non-voltage-dependent Ca2+ entry and receptor-mediated Ca2+ channel blocker SK&F-96365 (29) (20 µM); L-type voltage-gated Ca2+ channel blocker nifedipine (5 µM); and N-type voltage-gated Ca2+ channel blocker omega -conotoxin (36) (10 µM). Focus was placed on receptor-operated as well as N- and L-types voltage-gated Ca2+ channels since endothelial cells are not excitable and are essentially devoid of voltage-gated Ca2+ channels (18), whereas smooth muscle cells and astrocytes contain voltage-gated Ca2+ channels, mostly L and N type (14, 34).

Removal of the endothelium. The endothelium of newborn pig brain microvessels was chemically removed by intracarotid perfusion with 3-[(3-cholamidopropyl)-dimethylammonio]-2-hydroxy-1-propanesulphonate (CHAPS; 5 mg/l for 2 min) (32). After denudation, the vasomotor response of brain periventricular microvessels to C-PAF was studied. The removal of the endothelium was considered successful since the vasodilatory response to substance P (1 µM) (12) was absent while tissues responded normally to endothelium-independent stimulants U-46619 (0.2 µM) and sodium nitroprusside (1 µM).

Preparation of brain microvessel membrane. Microvessels from fetal, newborn, and adult brain were prepared as previously described (20, 24). Briefly, periventricular brain region was homogenized, preserving microvascular structure by homogenizing tissues in 5 mM Tris · HCl buffer (pH 7.4) containing 1.1 mM acetylsalicylic acid, 0.5 mM EGTA, 1 mM benzamidine, 0.1 mM phenylmethylsulfonyl fluoride, and 100 µg/ml soybean trypsin inhibitor with three up-and-down strokes with a tissue grinder (Wheaton, Teflon type). The homogenate was filtered through a nylon mesh filter (70 µm) and rinsed with the buffer above. Microvessels were collected from the nylon mesh, resuspended in the buffer above, rehomogenized with a hand pestle, centrifuged at 1,000 g for 15 min, and refiltered as above. The purified microvessels were collected, recentrifuged at 100,000 g for 45 min, and the pellet was stored at -80°C until used. The morphology and purity of microvessels were confirmed by light microscopy and a 15-fold higher level of gamma -glutamyl transpeptidase activity when compared with brain parenchyma, as described previously (24). The calibers of microvessels used ranged from 20 to 60 µm in diameter.

Microvascular endothelial cell culture. Microvessels were suspended in selective endothelial or smooth muscle growth media (Clonetics). Confluent individual endothelial cells were trypsinized, centrifuged, reseeded in culture flasks, and subcultured; cell viability was verified by trypan blue exclusion and was >90%. Endothelial cells were identified by their cobblestone morphology at confluence, positive reactivity to factor VIII antibody, and negative reactivity to smooth muscle-specific actin and glial fibrillary acidic protein (GFAP) antibodies (Dako, Carpinteria, CA). Confluent cultures of endothelial cells from passages 5-15 were used for experiments.

[3H]PAF binding assay. Membranes were suspended in assay buffer, and proteins were measured by the dye-binding method using BSA as the standard. Saturation binding experiments were performed by incubating 200 µg of brain microvessel membrane proteins for 30 min at 37°C with increasing concentrations of [3H]PAF in the presence or absence of 25 µM unlabeled PAF; specific binding reached equilibrium within 10 to 15 min and remained stable for at least 30 min, as we previously reported (24). Reactions were terminated by the addition of 2.5 ml ice-cold 5 mM Tris · HCl buffer (pH 7.4). The incubates were rapidly filtered through Whatman GF/C glass filter disks and washed three times with 2.5 ml of the same buffer. The radioactivity on the filter disks was counted with a beta counter (Beckman LS6000IC). Receptor densities (maximal binding; Bmax) and dissociation constants (Kd) were determined from the saturation isotherms (24) using a computer program (Prism, GraphPad).

Inositol phosphate assay. PAF receptor activation can be coupled to inositol phosphate production (8, 30). Inositol phosphate formation was determined on periventricular tissues from fetal, newborn, and adult pigs. Tissues were homogenized and incubated with [3H]inositol for 18 h, followed by stimulation with C-PAF (0.1, 1, and 10 µM) for 20 min. Inositol phosphates were then extracted with chloroform/methanol (1:1) and purified with an anionic exchange resin (AG 1-×8) (Bio-Rad, Hercules, CA). The inositol phosphate production was assessed with a scintillation counter.

Thromboxane assay. Effects of C-PAF on thromboxane formation were studied in fetus, newborn, and adult pig brain slices stimulated (15 min) with C-PAF at 0.1, 1, and 10 µM; the reaction was terminated with liquid N2. Thromboxane B2 (stable TXA2 metabolite) was assessed on homogenized tissue by radioimmunoassay as previously described (1, 20). TXB2 concentration was also measured in newborn pig brain slices stimulated for 15 min with C-PAF (1 µM) in the presence of CGS-12970 (1 µM), SK&F-96365 (20 µM), omega -conotoxin (10 µM), or nifedipine (5 µM).

Immunoblotting of thromboxane synthase. TXA2 synthase immunoreactivity on brain was determined as we previously described for other membrane-bound enzymes (33). Briefly, homogenized tissues from the periventricular regions of all age groups studied were preabsorbed with 50 ml of immunoprecipitin for 30 min and then centrifuged at 12,000 g for 10 min to remove the immunoprecipitin. The supernatant was incubated with porcine TXA2 synthase-specific polyclonal antibodies (Cayman Chemicals) for 1.5 h, and immune complexes were collected by incubation with 50 ml immunoprecipitin for 30 min, followed by centrifugation. Immune precipitates were denatured in SDS buffer, centrifuged at 12,000 g for 15 min to remove the immunoprecipitin, and the samples were loaded on SDS-polyacrylamide gels. The proteins were electrophoretically transferred to nitrocellulose membranes and incubated with TXA2 synthase-specific antibodies. After being washed, the membrane was incubated with horseradish peroxidase-conjugated anti-rabbit IgG antibody followed by several washes. Immunoreactive bands were visualized by enhanced chemiluminescence (Amersham) as recommended by the supplier and analyzed by densitometry.

Ca2+ signals. Intracellular Ca2+ ([Ca2+]i) signals were measured using the fluorescent indicator fura 2-AM as we have reported (20). For this purpose, confluent endothelial cells of newborn pigs were trypsinized in a solution containing 0.05% trypsin and 0.02% EDTA for 2 min, then 5 ml of HBSS was added. Cells were centrifuged at 250 g for 10 min and resuspended in a buffer containing (in mmol/l) 20 HEPES, 10 D-glucose, 4.6 KCl, 118 NaCl, and 0.5 CaCl2, as well as 1% fetal bovine serum. Cell viability was determined by trypan blue exclusion and was >90%. Fura 2-AM (2 µmol/l) and 0.2% Pluronic F-127 were added to cell suspensions, which were incubated at 37°C for 30 min. The loaded cells were then washed twice and resuspended in HBSS with Ca2+ (2.5 mM) and 1% fetal bovine serum with or without a 15-min pretreatment with SK&F-96365 (20 µM), nifedipine (5 µM), or omega -conotoxin (10 µM), followed by stimulation with C-PAF (1 µM). The [Ca2+]i was determined in 2 ml of fura 2-AM-loaded cell suspension (~2 × 106 cells/ml) continuously stirred and measured with a spectrofluorometer (model LS 50, Perkin-Elmer, Beaconsfield, UK) by using excitation wavelengths of 340 and 380 nm and emission at 510 nm. Calibration of the fluorescent signal was determined using 10 mM ionomycin and 5 mM EGTA plus 0.2% Triton X-100 to obtain a maximal and minimal fluorescence ratio. The [Ca2+]i was calculated as reported (16).

Chemicals. L-670596 and CGS-12970 were generous gifts from Merck-Frosst (Pointe-Claire, PQ, Canada) and Ciba-Geigy (Summit, NJ), respectively. THG-315 was a gift from Theratechnologies (Saint-Laurent, PQ, Canada). The following products were purchased: C-PAF and SK&F-96365 (BioMol, Plymouth Meeting, PA); U-46619 and PGF2alpha (Cayman Chemicals); ATP, EDTA, EGTA, ionomycin, nifedipine, Triton X-100, omega -conotoxin, Tris · HCl, and CHAPS (Sigma Chemical, St. Louis, MO); fura 2-AM (Calbiochem, La Jolla, CA); TXB2 radioimmunoassay kits (Amersham, Oakville, ON, Canada); endothelial, smooth muscle cells (Clonetics); Factor VIII antibody, smooth muscle-specific actin antibody, and GFAP antibody (Dako); all other chemicals (Fisher Scientific, Montreal, PQ, Canada).

Statistics. All results are expressed as means ± SE. Results were analyzed using Student's t-test and two-way ANOVA factoring for concentrations and age or treatments. Post-ANOVA comparisons among means were performed using the Tukey-Kramer method. P values <0.05 were considered to be significant.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Effects of PAF on brain periventricular microvessels. C-PAF caused concentration-dependent constriction of periventricular microvessels from fetal and newborn pigs, whereas vasoconstriction of adult pig microvessels was negligible (Fig. 1A). Emax values for fetus, newborn, and adult were 29.27 ± 2.6, 22.14 ± 3.2, and 2.3 ± 0.8%. The EC50 values of C-PAF on fetal and newborn pig microvessels were comparable: 25.96 ± 0.9 and 19.95 ± 1.4 nM. In contrast, PGF2alpha was more effective on adult than fetal and newborn pig microvessels (P < 0.05) (Fig. 1B), and U-46619 was equivalently effective on tissues of all three age groups. Because PAF has been shown to increase the production of vasodilator prostaglandins and nitric oxide (30) in several tissues, we tested whether there were ontogenic changes in relaxant response to C-PAF; C-PAF did not elicit vasorelaxation, whereas substance P (1 µM) relaxed brain microvessels of all ages (data not shown).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   Vasoconstrictor response to C-platelet-activating factor (C-PAF), PGF2alpha , and U-46619 on brain periventricular microvessels of fetal, neonatal, and adult pigs. Constriction is the percent reduction in vascular diameter from basal values that were 38.4 ± 3.1, 37.5 ± 4.1, and 35.1 ± 3.8 µm, respectively, for fetus, newborn, and adult. Effects of agents were studied in situ on brain slices as described in MATERIALS AND METHODS. Data are means ± SE of 5-6 separate experiments. *P < 0.01 compared with fetal and newborn pigs; dagger P < 0.05 compared with fetal and adult pigs (2-way ANOVA and comparison among means test).

Specific [3H]PAF binding on brain microvessels and inositol phosphate production. To explain the difference in the response of fetal, newborn, and adult brain microvessels to C-PAF, we compared PAF receptor density and the production of the second messenger inositol phosphate in fetal, newborn, and adult tissues. Maximum specific binding of [3H]PAF to brain microvessel membranes was greater in fetus (Bmax 551.5 ± 36.2 fmol/mg protein) than in newborn (Bmax 423.1 ± 60.6 fmol/mg protein), which was three times greater than in adult (Bmax 180.0 ± 37.3 fmol/mg protein) (Fig. 2A). Dissociation constants (Kd, nM) were comparable: 28.61 ± 5.2, 27.27 ± 4.8, and 18.11 ± 4.1, respectively, in fetal, newborn, and adult tissues. PAF-induced inositol phosphate production exhibited an age-dependent profile that was greater in fetal than in newborn and minimally present in adult tissues (Fig. 2B).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2.   A: saturation curves of [3H]PAF binding to brain microvessel membrane preparations from fetal, newborn, and adult pigs. Each point is the means ± SE of 4 separate experiments. B: effects of C-PAF on net inositol phosphate production by periventricular tissues from fetal, newborn, and adult pigs. Data are means ± SE of 4 separate experiments. *P < 0.01 compared with corresponding values for newborn and fetus; dagger P < 0.05 compared with corresponding values for fetus and adult; Dagger P < 0.01 compared with lower concentrations of C-PAF (2-way ANOVA and comparison among means test).

TXA2-mediated vasoconstriction to PAF. The vasoconstrictor effects of PAF on the microvessels from fetal and newborn pigs were almost fully inhibited by TXA2 synthase inhibitor CGS-12970 and TXA2 receptor antagonist L-670596 (Fig. 3, A and B). The role of TXA2 in PAF-induced constriction was not studied in adults given the negligible vasoconstriction in this age group. In addition, PAF-induced constriction was virtually abolished by endothelial denudation (Fig. 3C) as demonstrated in newborn tissues. Moreover, TXB2 levels increased dose dependently after stimulation of the fetal and newborn periventricular tissue with PAF (Fig. 4A). In contrast, TXB2 levels were only mildly increased by PAF stimulation in adult tissues (Fig. 4A). A similar developmental pattern of immunoreactive TXA2 synthase expression was observed (Fig. 4, B and C). Hence, developmental differences in PAF-induced constriction appear to depend on ontogenic differences in TXA2 formation, which seems to be generated largely by the endothelium.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   A and B: contribution of thromboxane A2 (TXA2) in PAF-induced periventricular microvascular constriction of newborn and fetus; adults were virtually unresponsive to C-PAF. Tissues were pretreated 20 min with saline (control), thromboxane synthase inhibitor CGS-12970 (1 µM), thromboxane receptor antagonist L-670596 (0.1 µM), or PAF receptor blocker THG-315 (1 µM). Experimental preparations are similar to those for Fig 1. Data are means ± SE of 5-6 separate experiments. *P < 0.01 compared with saline-treated preparations (2-way ANOVA). C: deendothelialization of brain vasculature was performed by intracarotid perfusion with 3-[(3-cholamidopropyl)-dimethylammonio]-2-hydroxy-1-propanesulphonate (5 mg/l for 2 min; see MATERIALS AND METHODS). Data are means ± SE of 5-6 separate experiments. *P < 0.01 compared with values for control (2-way ANOVA).



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4.   A: effects of C-PAF on thromboxane formation. B and C: representative immunoblot and relative densitometry of thromboxane synthase in periventricular brain region of fetal, newborn, and adult pigs. A: data are means ± SE of 5-6 separate experiments. *P < 0.01 compared with corresponding values for newborn and fetus; dagger P < 0.05 compared with corresponding values for fetus and adult; Dagger P < 0.05 compared with C-PAF at 0.1 µM (2-way ANOVA and comparison among means test). B: representative immunoblot of 3 experiments. C: compiled densitometry of the immunoblots relative to that of the fetus set at 100%. dagger P < 0.05 compared with corresponding values for fetus and adult.

Involvement of Ca2+ on PAF-induced TXA2 formation and vasoconstriction. Because removal of the endothelium completely abolished the TXA2-dependent action of C-PAF, endothelial cells must contribute to the TXA2 formation evoked by C-PAF (Fig. 3C). Because enzyme-catalyzed prostanoid formation is Ca2+ dependent via phospholipase A2, we attempted to identify the type of Ca2+ channel involved in PAF-induced TXA2 generation and vasoconstriction. PAF-induced increase in TXB2 formation in periventricular tissue of newborn pigs was markedly inhibited by CGS-12970, putative receptor-operated Ca2+ channel blocker SK&F-96365 (29), and by the Ca2+ chelator EGTA, but not by selective N-type voltage-gated Ca2+ channel blocker omega -conotoxin MVIIA (36) or L-type voltage-gated Ca2+ channel blocker nifedipine (Fig. 5A); similar inhibition of PAF-induced increase in TXB2 formation was observed in the fetus when we tested SK&F-96365 in contrast to omega -conotoxin MVIIA (not shown). Accordingly, vasoconstriction to C-PAF was also nearly abolished by SK&F-96365 but was unaffected by omega -conotoxin MVIIA in young animals (Fig. 5C). Vasoconstriction to C-PAF and TXA2 mimetic U-46619 was inhibited by nifedipine (Fig. 5C).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   A: effects of C-PAF on TXB2 production by periventricular tissues from newborn pig brain. Tissues were pretreated 20 min with saline or one of the following: CGS-12970 (1 µM), SK&F-96365 (20 µM), EGTA (100 µM), omega -conotoxin (10 µM), and nifedipine (5 µM). Data are means ± SE of 5-6 separate experiments. *P < 0.01 compared with all other values without asterisk. B: intracellular peak calcium transients [Ca2+]i in newborn pig brain endothelial cells in response to C-PAF (0.1 and 1 µM) using fura 2-AM (see MATERIALS AND METHODS). Cells were pretreated 20 min with SK&F-96365 (20 µM), EGTA (100 µM), omega -conotoxin (10 µM), and nifedipine (5 µM). Values are means ± SE of 4-5 separate experiments. *P < 0.01 compared with basal value; dagger P < 0.01 compared with other values other than basal. C: vasoconstrictor response of periventricular microvessels of newborn pigs to C-PAF and U-46619 in the presence of saline, SK&F-96365 (20 µM), nifedipine (5 µM), or omega -conotoxin (10 µM); effects of agents were studied in situ on brain slices as described in MATERIALS AND METHODS. Data are means ± SE of 5-6 separate experiments. *P < 0.01 compared with C-PAF + saline as well as with C-PAF + omega -conotoxin (2-way ANOVA and comparison among means tests).

The effects of C-PAF on Ca2+ transients corroborated the data on TXB2 formation. C-PAF induced an increase in Ca2+ signals in endothelial cells, which was significantly reduced by SK&F-96365 and EGTA, but not by nifedipine or omega -conotoxin (Fig. 5B). In contrast, C-PAF did not affect Ca2+ transients in smooth muscle cells. On the other hand, TXA2 mimetic U-46619 (1 µM) induced Ca2+ transients in smooth muscle cells, which were inhibited by nifedipine (5 µM), but not by SK&F-96365 (20 µM) (data not shown).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

PAF is an important phospholipid with diverse physiological and pathological roles in vivo, including effects on circulation (5, 22, 30). Due to its potent actions on blood vessels, PAF might be a putative mediator in ischemic brain injury (25, 26). Little is known about the effects of PAF on brain intraparenchymal microvessels during development. The present study reveals that PAF causes greater constriction of fetus and newborn periventricular microvessels compared with those of adult animals as a result of a higher density of PAF receptor and greater thromboxane generation, principally of endothelial origin, via activation of receptor-operated Ca2+ channels.

PAF exerts its effects by interacting with a specific PAF receptor (30). Depending on the species and tissues, PAF causes constriction or dilation according to different coupling mechanisms (5, 22, 26). For instance, PAF is a potent constrictor of cerebral arterioles in newborn pigs (5) and produces vasodilatation in mesenteric circulation in dogs (30). In some tissues (e.g., coronary and cerebral vessels), vasoconstriction evoked by PAF is partly mediated by TXA2 (22, 26). In the present study, effects of PAF on periventricular microvasculature are also mediated via TXA2, which is released from endothelial cells (Figs. 3 and 4A). This inference is based on the following observations: 1) PAF stimulates calcium-dependent thromboxane production (Fig. 5, A and B); 2) periventricular vasoconstriction to PAF is thromboxane dependent (Fig. 3, A and B); 3) PAF-induced Ca2+ signals, thromboxane formation, and vasoconstriction are abrogated by non-voltage-gated calcium channel blocker SK&F-96365, consistent with absence of voltage-gated calcium channels in endothelium (40); 4) removal of endothelium abolishes effects of PAF as seen with TXA2 synthase and receptor blockers (Fig. 3A); and 5) PAF-induced Ca2+ transients and thromboxane formation were not inhibited by selective N-type voltage-gated Ca2+ channel blocker omega -conotoxin MVIIA (36) or L-type voltage-gated Ca2+ channel blocker nifedipine (Fig. 5, A and B), suggesting that perivascular astrocytes that contain N- and L-type voltage-gated Ca2+ channels (34, 43) are not contributors to the TXA2 formation (20). Accordingly, the efficacy of nifedipine in PAF-evoked vasoconstriction, but not thromboxane formation, concurs with the action of PAF-generated thromboxane on L-type voltage-gated Ca2+ channels in smooth muscle (21). Taken together, these data suggest that PAF increases the influx of calcium through receptor-operated channels in endothelial cells, and this, in turn, enhances the formation of thromboxane.

An important observation in this study is the greater constriction evoked by PAF in the fetus compared with the newborn, which is markedly larger than that in adult pigs (Fig. 1A); results in the adult pig are in agreement with the unresponsiveness of mature rats (13). These findings are of interest because the constrictor responses to a number of agents, such as adrenergic agonists, serotonin, angiotensin, and prostaglandin F2alpha (Fig. 1B), are often reduced on the blood vessels of younger subjects compared with those of adult animals (2, 9, 39). Specific binding of [3H]PAF to brain microvessel membranes revealed a greater density of PAF receptor in younger than adult animals (Fig. 2A); mechanisms for this developmental change remain to be clarified. However, simply a lower density of PAF receptor in adults could not per se explain the lack of vasoconstriction to PAF (Fig. 1A). On the other hand, the virtual absence of PAF-induced thromboxane formation due to diminished thromboxane synthase protein expression and associated inositol phosphate production in mature animals is consistent with the vasomotor response to PAF (Figs. 2 and 4), whereas effects of thromboxane seem preserved throughout development (Fig. 1C), as previously reported (20). Hence, developmental changes in PAF-induced brain microvascular constriction seem partly dependent on ontogenic differences in PAF receptor density, but maybe mostly due to the greater thromboxane synthase expression observed in younger subjects (Fig. 4B). The reason for increased expression of TXA2 synthase in the periventricular brain region of immature subjects is not clear. However, its role in the migration of astrocytes from the germinal matrix in the periventricular region to others in the developing brain has been proposed (27). We speculate that the markedly greater PAF-induced brain microvascular constriction in the younger subjects may contribute to the hemodynamic compromise and periventricular brain injury observed in premature neonates exposed to oxidant stress. PAF antagonists, thromboxane synthase inhibitor, and/or receptor blockers may attenuate the deleterious effects of oxidant stress (4, 25, 28).


    ACKNOWLEDGEMENTS

We thank H. Fernandez for technical assistance.


    FOOTNOTES

This work was supported by grants from the Canadian Institutes of Health Research, the March of Dimes Birth Defects Foundation, the Heart and Stroke Foundation of Quebec, and the Fonds de la Recherche en Santé du Québec. D. Checchin, C. Quiniou, and S. Brault are recipients, respectively, of studentships from the National Science and Engineering Research Council of Canada, the Heart and Stroke Foundation of Canada, and the Research Center of Hôpital Sainte-Justine. A. M. Marrache, S. G. Bernier, F. Gobeil Jr., and S. Chemtob are recipients, respectively, of studentship, fellowship, and scientist awards from the Canadian Institutes of Health Research. S. Chemtob also holds a Canada Research Chair.

Address for reprint requests and other correspondence: S. Chemtob, Research Center, Hôpital Sainte-Justine, Dept. of Pediatrics and Pharmacology, 3175 Côte Sainte-Catherine, Montréal, Québec, Canada, H3T 1C5 (E-mail: sylvain.chemtob{at}umontreal.ca).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

10.1152/ajpregu.00633.2002

Received 11 October 2002; accepted in final form 18 December 2002.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Abran, D, Varma DR, and Chemtob S. Increased thromboxane-mediated contractions of retinal vessels of newborn pigs to peroxides. Am J Physiol Heart Circ Physiol 268: H628-H632, 1995[Abstract/Free Full Text].

2.   Abran, D, Varma DR, Li DY, and Chemtob S. Reduced responses of retinal vessels of the newborn pig to prostaglandins but not to thromboxane. Can J Physiol Pharmacol 72: 168-173, 1994[Web of Science][Medline].

3.   Akiba, S, Nagatomo R, Hayama M, and Sato T. Stimulation of cytosolic phospholipase A2-catalyzed arachidonic acid liberation by low dose tert-butyl hydroperoxide without an influence on the enzyme activity in rabbit platelets. Biochem Mol Biol Int 43: 799-806, 1997[Web of Science][Medline].

4.   Akisu, M, Kultursay N, Coker I, and Huseyinov A. Platelet-activating factor is an important mediator in hypoxic ischemic brain injury in the newborn rat. Flunarizine and Ginkgo biloba extract reduce PAF concentration in the brain. Biol Neonate 74: 439-444, 1998[Web of Science][Medline].

5.   Armstead, WM, Pourcyrous M, Mirro R, Leffler CW, and Busija DW. Platelet activating factor: a potent constrictor of cerebral arterioles in newborn pigs. Circ Res 62: 1-7, 1988[Abstract/Free Full Text].

6.   Blank, ML, Lee T, Fitzgerald V, and Snyder F. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J Biol Chem 256: 175-178, 1981[Abstract/Free Full Text].

7.   Bonventre, JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, and Sapirstein A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 390: 622-625, 1997[Medline].

8.   Chao, W, and Olson MS. Platelet-activating factor: receptors and signal transduction. Biochem J 292: 617-629, 1993[Web of Science][Medline].

9.   Chemtob, S, Guest I, Potvin W, and Varma DR. Ontogeny of responses of rabbit aorta to atrial natriuretic factor and isoproterenol. Dev Pharmacol Ther 16: 108-115, 1991[Web of Science][Medline].

10.   Clavijo, LC, Carter MB, Matheson PJ, Wills-Frank LA, Wilson MA, Wead WB, and Garrison RN. Platelet-activating factor and bacteremia-induced pulmonary hypertension. J Surg Res 88: 173-180, 2000[Web of Science][Medline].

11.   Dillon, PK, Ritter AB, and Duran WN. Vasoconstrictor effects of platelet-activating factor in the hamster cheek pouch microcirculation: dose-related relations and pathways of action. Circ Res 62: 722-731, 1988[Abstract/Free Full Text].

12.   Dumont, I, Hou X, Hardy P, Peri KG, Beauchamp M, Najarian T, Molotchnikoff S, Varma DR, and Chemtob S. Developmental regulation of endothelial nitric oxide synthase in cerebral vessels of newborn pig by prostaglandin E2. J Pharmacol Exp Ther 291: 627-633, 1999[Abstract/Free Full Text].

13.   Edwards, RM, Trizna W, and Feuerstein G. Platelet-activating factor (PAF) has no direct effect on rat intracerebral arterioles in vitro. J Lipid Mediators 3: 161-165, 1991[Web of Science][Medline].

14.   Fern, R. Intracellular calcium and cell death during ischemia in neonatal rat white matter astrocytes in situ. J Neurosci 18: 7232-7243, 1998[Abstract/Free Full Text].

15.   Fox, JA. Novel omega-conopeptides reduced field potential amplitudes in the rat hippocampal slice. Neurosci Lett 165: 157-160, 1994[Web of Science][Medline].

16.   Grynkiewicz, G, Poenie M, and Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450, 1985[Abstract/Free Full Text].

17.   Harper, SL, Bohlen HG, and Rubin MJ. Arterial and microvascular contributions to cerebral cortical autoregulation in rats. Am J Physiol Heart Circ Physiol 246: H17-H24, 1984[Abstract/Free Full Text].

18.   Himmel, HM, Whorton AR, and Strauss HC. Intracellular calcium, currents, and stimulus-response coupling in endothelial cells. Hypertension 21: 112-127, 1993[Abstract/Free Full Text].

19.   Hoffman, SW, Moore S, and Ellis EF. Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles. Stroke 28: 844-849, 1997[Abstract/Free Full Text].

20.   Hou, X, Gobeil F, Jr, Peri K, Speranza G, Marrache AM, Lachapelle P, Roberts J, II, Varma DR, and Chemtob S. Augmented vasoconstriction and thromboxane formation by 15-F(2t)-isoprostane (8-iso-prostaglandin F2alpha ) in immature pig periventricular brain microvessels. Stroke 31: 516-524, 2000[Abstract/Free Full Text].

21.   Hughes, AD. Calcium channels in vascular smooth muscle cells. J Vasc Res 32: 353-370, 1995[Web of Science][Medline].

22.   Kinn, JW, and Bache RJ. Effect of platelet activation on coronary collateral blood flow. Circulation 98: 1431-1437, 1998[Abstract/Free Full Text].

23.   Leffler, CW, Busija DW, Armstead WM, and Mirro R. H2O2 effects on cerebral prostanoids and pial arteriolar diameter in piglets. Am J Physiol Heart Circ Physiol 258: H1382-H1387, 1990[Abstract/Free Full Text].

24.   Li, DY, Varma DR, and Chemtob S. Ontogenic increase in PGE2 and PGF2alpha receptor density in brain microvessels of pigs. Br J Pharmacol 112: 59-64, 1994[Web of Science][Medline].

25.   Liu, XH, Eun BL, Silverstein FS, and Barks JD. The platelet-activating factor antagonist BN 52021 attenuates hypoxic-ischemic brain injury in the immature rat. Pediatr Res 40: 797-803, 1996[Web of Science][Medline].

26.   Matsuo, Y, Kihara T, Ikeda M, Ninomiya M, Onodera H, and Kogure K. Role of platelet-activating factor and thromboxane A2 in radical production during ischemia and reperfusion of the rat brain. Brain Res 709: 296-302, 1996[Web of Science][Medline].

27.   McDonough, W, Tran N, Giese A, Norman SA, and Berens ME. Altered gene expression in human astrocytoma cells selected for migration. I. Thromboxane synthase. J Neuropathol Exp Neurol 57: 449-455, 1998[Web of Science][Medline].

28.   Ment, LR, Stewart WB, Petroff OA, and Duncan CC. Thromboxane synthesis inhibitor in a beagle pup model of perinatal asphyxia. Stroke 20: 809-814, 1989[Abstract/Free Full Text].

29.   Merritt, JE, Armstrong WP, Benham CD, Hallam TJ, Jacob R, Jaxa-Chamiec A, Leigh BK, McCarthy SA, Moores KE, and Rink TJ. SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. Biochem J 271: 515-522, 1990[Web of Science][Medline].

30.   Montrucchio, G, Alloatti G, and Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 80: 1669-1699, 2000[Abstract/Free Full Text].

31.   Murphy, S, Pearce B, Jeremy J, and Dandona P. Astrocytes as eicosanoid-producing cells. Glia 1: 241-245, 1988[Web of Science][Medline].

32.   Okazaki, K, Endou M, and Okumura F. 1998 Involvement of barium-sensitive K+ channels in endothelium-dependent vasodilation produced by hypercapnia in rat mesenteric vascular beds. Br J Pharmacol 125: 168-174, 1998[Web of Science][Medline].

33.   Peri, K, Hardy P, Li DY, Varma DR, and Chemtob S. Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandins in the newborn. J Biol Chem 270: 24615-24620, 1995[Abstract/Free Full Text].

34.   Porter, JT, and McCarthy KD. Hippocampal astrocytes in situ respond to glutamate released from synaptic terminals. J Neurosci 16: 5073-5081, 1996[Abstract/Free Full Text].

35.   Predescu, D, Ihida K, Predescu S, and Palade GE. The vascular distribution of the platelet-activating factor receptor. Eur J Cell Biol 69: 86-98, 1996[Web of Science][Medline].

36.   Rivier, J, Galyean R, Gray WR, Azimi-Zonooz A, McIntosh JM, Cruz LJ, and Olivera BM. Neuronal calcium channel inhibitors. Synthesis of omega-conotoxin GVIA and effects on 45Ca uptake by synaptosomes. J Biol Chem 262: 1194-1198, 1987[Abstract/Free Full Text].

37.   Sano, K, Asano T, Tanishima T, and Sasaki T. Lipid peroxidation as a cause of cerebral vasospasm. Neurol Res 2: 253-272, 1980[Medline].

38.   Sullivan, JL. Iron, plasma antioxidants, and the oxygen redical disease of prematurity. Am J Dis Child 142: 1341-1344, 1988[Abstract/Free Full Text].

39.   Toda, N, and Hayashi S. Age-dependent alteration in the response of isolated rabbit basilar arteries to vasoactive agents. J Pharmacol Exp Ther 211: 716-721, 1979[Abstract/Free Full Text].

40.   Tran, QK, Ohashi K, and Watanabe H. Calcium signalling in endothelial cells. Cardiovasc Res 48: 13-22, 2000[Abstract/Free Full Text].

41.   Vannucci, RC, and Perlman JM. Interventions for perinatal hypoxic-ischemic encephalopathy. Pediatrics 100: 1004-1014, 1997[Free Full Text].

42.   Volpe, JJ. Brain injury in the premature infant: overview of clinical aspects, neuropathology, and pathogenesis. Semin Pediatr Neurol 5: 135-151, 1998[Medline].

43.   Westenbroek, RE, Bausch SB, Lin RC, Franck JE, Noebels JL, and Catterall WA. Upregulation of L-type Ca2+ channels in reactive astrocytes after brain injury, hypomyelination, and ischemia. J Neurosci 18: 2321-2334, 1998[Abstract/Free Full Text].


Am J Physiol Regul Integr Comp Physiol 284(4):R928-R935
0363-6119/03 $5.00 Copyright © 2003 the American Physiological Society



This article has been cited by other articles:


Home page
J. Neurosci.Home page
M. Ahn, D. Beacham, R. E. Westenbroek, T. Scheuer, and W. A. Catterall
Regulation of NaV1.2 Channels by Brain-Derived Neurotrophic Factor, TrkB, and Associated Fyn Kinase
J. Neurosci., October 24, 2007; 27(43): 11533 - 11542.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hou, X.
Right arrow Articles by Chemtob, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hou, X.
Right arrow Articles by Chemtob, S.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online